Welcome to our dedicated page for AN2 Therapeutics SEC filings (Ticker: ANTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
AN2 Therapeutics, Inc. filings document the regulatory record of a Nasdaq-listed clinical-stage biopharmaceutical company developing small-molecule therapeutics from a boron chemistry platform. Its disclosures cover common stock registration, operating and financial results, clinical and regulatory updates, risk factors and material events related to its development pipeline.
ANTX filings also include proxy materials for director elections and auditor ratification, 8-K reports on material agreements, equity and warrant financing arrangements, at-the-market sale agreements, equity incentive plan matters, option repricing, officer appointments, governance changes and capital-structure disclosures.
AN2 Therapeutics ownership disclosure: an amendment shows Almitas Capital LLC beneficially owns 1,479,129 shares of common stock, representing 4.1% of the class. The filing lists sole voting and sole dispositive power over 1,479,129 shares. The filing is signed by Ronald Mass as Managing Principal on 05/15/2026.
AN2 Therapeutics reported a Q1 2026 net loss of $10.0M, slightly improved from $10.6M a year earlier, as operating expenses declined modestly. Research and development was $6.7M, reflecting its focus on advancing a boron-chemistry small-molecule pipeline across hematologic, infectious disease, and oncology indications.
Cash, cash equivalents and investments totaled $85.3M as of March 31, 2026, boosted by a March 2026 private placement that raised roughly $40.0M in gross proceeds through common stock and pre-funded warrants. Management believes this cash will fund the current operating plan for at least twelve months.
Clinically, AN2 plans a Phase 2 proof-of-concept study of epetraborole in polycythemia vera starting in Q3 2026, supports an investigator-initiated trial in M. abscessus lung disease with topline data expected in late 2027, and has completed Phase 1 dosing of AN2-502998 for chronic Chagas disease ahead of Phase 1/NHP data in Q2 2026 and a planned Phase 2 later in 2026. The company also declared an ENPP1 oncology candidate and continues discussions with U.S. agencies to fund Phase 2 development of epetraborole for acute melioidosis.
AN2 Therapeutics reported first quarter 2026 results showing a net loss of $10.0 million, slightly improved from $10.6 million a year earlier, as research and development spending declined to $6.7 million while general and administrative costs held steady at $3.8 million.
Cash, cash equivalents and investments totaled $85.3 million at March 31, 2026, supported by $40.0 million of gross proceeds from a March private placement, which the company expects will fund operations into 2029. AN2 highlighted progress across its boron chemistry pipeline, including plans to move oral epetraborole into Phase 2 for polycythemia vera, an investigator-initiated Phase 2 trial in M. abscessus lung disease, upcoming Phase 1 and non-human primate data for AN2-502998 in chronic Chagas disease, and declaration of an ENPP1 candidate for solid tumors.
AN2 Therapeutics, Inc. is asking stockholders to vote at its 2026 Annual Meeting on June 3, 2026, at 8:00 a.m. Pacific Time in Menlo Park, California. Investors will elect three Class I directors to terms running until the 2029 annual meeting and ratify PricewaterhouseCoopers LLP as independent auditor for fiscal 2026. Stockholders of record at the close of business on April 15, 2026, when 35,995,545 common shares were outstanding and entitled to vote, may cast votes by internet, telephone, mail, or in person. The proxy also details board structure, committee membership, executive compensation, equity awards, and severance and change-in-control protections for senior management.
AN2 Therapeutics, Inc. is registering 14,035,104 shares of common stock for resale by selling securityholders pursuant to a registration rights agreement. The amount comprises 8,245,611 issued shares and 5,789,493 shares issuable upon exercise of pre-funded warrants. The company is not selling any shares and will receive no proceeds from resales; however, upon exercise of the pre-funded warrants AN2 will receive the nominal cash exercise price paid by holders.
AN2 Therapeutics is offering up to $80,000,000 of common stock in an at‑the‑market (ATM) program under a sales agreement with Jefferies LLC. Shares may be sold from time to time at market prices through Jefferies acting as agent or principal; Jefferies may receive up to 3.0% of gross proceeds as compensation. The prospectus supplement ties this $80,000,000 ATM to the company’s existing $300,000,000 shelf registration.
For context, AN2 had 27,413,171 shares outstanding as of December 31, 2025; subsequent private placements sold 8,245,611 shares and pre‑funded warrants to purchase up to 5,789,493 shares. The company states net proceeds are intended to fund research and development, working capital and general corporate purposes.
Aziz Kabeer reported acquisition or exercise transactions in this Form 4 filing.
AN2 Therapeutics director Aziz Kabeer received 3,775 shares of Common Stock as an equity grant. The shares were issued in lieu of cash under the non-employee director compensation policy and vest immediately. Following this award, he holds 56,254 shares directly.
Separate from his direct holdings, 1,995,958 shares are held by Adjuvant Global Health Technology Fund, L.P. and 377,542 shares are held by Adjuvant Global Health Technology Fund DE, L.P. Mr. Kabeer is affiliated with these entities and may be deemed to share voting and dispositive power, but each person and entity disclaims beneficial ownership except for any pecuniary interest.
Marks Gilbert Lynn reported acquisition or exercise transactions in this Form 4 filing.
AN2 Therapeutics director Gilbert Lynn Marks received a stock grant of 3,775 shares of Common Stock on April 10, 2026. The shares were issued in lieu of cash under the company’s non-employee director compensation policy and carry a grant price of $0.00 per share.
All 3,775 shares vest immediately, meaning Marks has full ownership without a vesting schedule. Following this award, he directly holds a total of 79,084 shares of AN2 Therapeutics common stock. This is a compensation-related grant, not an open-market purchase.